{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:19:52Z","timestamp":1793848792156,"version":"4.6.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"am","delay-in-days":456,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009820","name":"Assistance publique-H\u00c3\u00b4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["INCA-DGOS_8663"],"award-info":[{"award-number":["INCA-DGOS_8663"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.beem.2020.101416","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T03:17:55Z","timestamp":1583810275000},"page":"101416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":179,"title":["An overview of 20\u00a0years of genetic studies in pheochromocytoma and paraganglioma"],"prefix":"10.1016","volume":"34","author":[{"given":"Alexandre","family":"Buffet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Burnichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Favier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Paule","family":"Gimenez-Roqueplo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.beem.2020.101416_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.beem.2020.101416_bib2","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-15-1841","article-title":"Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas","volume":"22","author":"Toledo","year":"2016","journal-title":"Clin Canc Res : an official journal of the American Association for Cancer Research"},{"issue":"20","key":"10.1016\/j.beem.2020.101416_bib3","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1158\/1078-0432.CCR-16-2250","article-title":"Targeted exome sequencing of Krebs cycle genes reveals candidate cancer-predisposing mutations in pheochromocytomas and paragangliomas","volume":"23","author":"Remacha","year":"2017","journal-title":"Clin Canc Res : an official journal of the American Association for Cancer Research"},{"issue":"12","key":"10.1016\/j.beem.2020.101416_bib4","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/s41436-018-0003-y","article-title":"Gain-of-function mutations in DNMT3A in patients with paraganglioma","author":"Remacha","year":"2018","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.beem.2020.101416_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ajhg.2019.02.017","article-title":"Recurrent germline DLST mutations in individuals with multiple pheochromocytomas and paragangliomas","volume":"104","author":"Remacha","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"8","key":"10.1016\/j.beem.2020.101416_bib6","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1158\/0008-5472.CAN-17-2463","article-title":"Germline mutations in the mitochondrial 2-oxoglutarate\/malate carrier SLC25A11 gene confer a predisposition to metastatic paragangliomas","volume":"78","author":"Buffet","year":"2018","journal-title":"Canc Res"},{"issue":"5","key":"10.1016\/j.beem.2020.101416_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv053","article-title":"Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene","volume":"107","author":"Cascon","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.beem.2020.101416_bib8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/cen.12530","article-title":"Testing for germline mutations in sporadic pheochromocytoma\/paraganglioma: a systematic review","volume":"82","author":"Brito","year":"2015","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2020.101416_bib9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.beem.2020.101416_bib10","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2020.101416_bib11","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.beem.2020.101416_bib12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.beem.2020.101416_bib13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1373\/clinchem.2010.153320","article-title":"Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma","volume":"57","author":"Eisenhofer","year":"2011","journal-title":"Clin Chem"},{"issue":"34","key":"10.1016\/j.beem.2020.101416_bib14","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","article-title":"Genetic testing in pheochromocytoma or functional paraganglioma","volume":"23","author":"Amar","year":"2005","journal-title":"J\u00a0Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.beem.2020.101416_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1677\/ERC-10-0211","article-title":"Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma","volume":"18","author":"Eisenhofer","year":"2011","journal-title":"Endocr Relat Canc"},{"issue":"19","key":"10.1016\/j.beem.2020.101416_bib16","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2020.101416_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archderm.141.1.71","article-title":"Prevalence of neurofibromatosis 1 in German children at elementary school enrollment","volume":"141","author":"Lammert","year":"2005","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.beem.2020.101416_bib18","first-page":"575","article-title":"Neurofibromatosis. Conference statement. National institutes of health consensus development conference","volume":"45","year":"1988","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.beem.2020.101416_bib19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1542\/peds.2007-3364","article-title":"Health supervision for children with neurofibromatosis","volume":"121","author":"Hersh","year":"2008","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.beem.2020.101416_bib20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1530\/EJE-16-0233","article-title":"Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1","volume":"175","author":"Kepenekian","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2020.101416_bib21","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-17-0714","article-title":"Next-generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1","volume":"178","author":"Gieldon","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2020.101416_bib22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"von Hippel-Lindau disease: a clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur J Hum Genet : EJHG (Eur J Hum Genet)"},{"issue":"11","key":"10.1016\/j.beem.2020.101416_bib23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/14992027.2013.824117","article-title":"von Hippel-Lindau disease: deafness due to a non-MRI-visible endolymphatic sac tumor despite targeted screening","volume":"52","author":"Binderup","year":"2013","journal-title":"Int J Audiol"},{"key":"10.1016\/j.beem.2020.101416_bib24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2018-03-838235","article-title":"New lessons from an old gene: complex splicing and a novel cryptic exon in VHL gene cause erythrocytosis and VHL disease","author":"Lenglet","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beem.2020.101416_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jmedgenet-2019-106519","article-title":"Germline mutations in the new E1' cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma","author":"Buffet","year":"2020","journal-title":"J\u00a0Med Genet"},{"issue":"3","key":"10.1016\/j.beem.2020.101416_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat Rev Canc"},{"issue":"12","key":"10.1016\/j.beem.2020.101416_bib27","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"6","key":"10.1016\/j.beem.2020.101416_bib28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association","volume":"19","author":"American Thyroid Association Guidelines Task","year":"2009","journal-title":"Thyroid : official journal of the American Thyroid Association."},{"issue":"4","key":"10.1016\/j.beem.2020.101416_bib29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jmoldx.2017.04.009","article-title":"PheoSeq: a targeted next-generation sequencing assay for pheochromocytoma and paraganglioma diagnostics","volume":"19","author":"Curras-Freixes","year":"2017","journal-title":"J\u00a0Mol Diagn : JMD."},{"issue":"8","key":"10.1016\/j.beem.2020.101416_bib30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/jmedgenet-2018-105714","article-title":"Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma","volume":"56","author":"Ben Aim","year":"2019","journal-title":"J\u00a0Med Genet"},{"issue":"10","key":"10.1016\/j.beem.2020.101416_bib31","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/ijc.29080","article-title":"Oncometabolites-driven tumorigenesis: from genetics to targeted therapy","volume":"135","author":"Morin","year":"2014","journal-title":"Int J Canc"},{"issue":"6","key":"10.1016\/j.beem.2020.101416_bib32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouze","year":"2013","journal-title":"Canc Cell"},{"issue":"5454","key":"10.1016\/j.beem.2020.101416_bib33","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.287.5454.848","article-title":"Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma","volume":"287","author":"Baysal","year":"2000","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.beem.2020.101416_bib34","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1210\/jc.2008-2504","article-title":"The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas","volume":"94","author":"Burnichon","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101416_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12881-014-0111-8","article-title":"Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations","volume":"15","author":"Bayley","year":"2014","journal-title":"BMC Med Genet"},{"issue":"2","key":"10.1016\/j.beem.2020.101416_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jmedgenet-2016-104297","article-title":"Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma","volume":"54","author":"Burnichon","year":"2017","journal-title":"J\u00a0Med Genet"},{"issue":"3","key":"10.1016\/j.beem.2020.101416_bib37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/jc.2005-1862","article-title":"Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes","volume":"91","author":"Benn","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101416_bib38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD","author":"Andrews","year":"2018","journal-title":"J\u00a0Med Genet"},{"issue":"17","key":"10.1016\/j.beem.2020.101416_bib39","first-page":"5615","article-title":"Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas","volume":"63","author":"Gimenez-Roqueplo","year":"2003","journal-title":"Canc Res"},{"issue":"2","key":"10.1016\/j.beem.2020.101416_bib40","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","article-title":"Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma","volume":"25","author":"Job","year":"2019","journal-title":"Clin Canc Res : an official journal of the American Association for Cancer Research"},{"issue":"10","key":"10.1016\/j.beem.2020.101416_bib41","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"31","key":"10.1016\/j.beem.2020.101416_bib42","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1200\/JCO.2011.34.6353","article-title":"Metastatic pheochromocytoma\/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations","volume":"29","author":"King","year":"2011","journal-title":"J\u00a0Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.beem.2020.101416_bib43","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"15","key":"10.1016\/j.beem.2020.101416_bib44","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/hmg\/ddq206","article-title":"SDHA is a tumor suppressor gene causing paraganglioma","volume":"19","author":"Burnichon","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.beem.2020.101416_bib45","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1210\/jc.2017-01762","article-title":"Clinical aspects of SDHA-related pheochromocytoma and paraganglioma: a nationwide study","volume":"103","author":"van der Tuin","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.beem.2020.101416_bib46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1158\/1078-0432.CCR-10-0420","article-title":"SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma","volume":"17","author":"Kunst","year":"2011","journal-title":"Clin Canc Res : an Official Journal of the American Association for Cancer Research"},{"issue":"9","key":"10.1016\/j.beem.2020.101416_bib47","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamaoncol.2017.0223","article-title":"Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention","volume":"3","author":"Bausch","year":"2017","journal-title":"JAMA oncology"},{"issue":"12","key":"10.1016\/j.beem.2020.101416_bib48","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/PAS.0000000000000292","article-title":"Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients","volume":"38","author":"Gill","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.beem.2020.101416_bib49","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","article-title":"Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic","volume":"2","author":"Boikos","year":"2016","journal-title":"JAMA oncology"},{"issue":"3","key":"10.1016\/j.beem.2020.101416_bib50","doi-asserted-by":"crossref","first-page":"E357","DOI":"10.1210\/jc.2011-1179","article-title":"Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH?","volume":"97","author":"Xekouki","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.beem.2020.101416_bib51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng.533","article-title":"Germline mutations in TMEM127 confer susceptibility to pheochromocytoma","volume":"42","author":"Qin","year":"2010","journal-title":"Nat Genet"},{"issue":"23","key":"10.1016\/j.beem.2020.101416_bib52","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1001\/jama.2010.1830","article-title":"Spectrum and prevalence of FP\/TMEM127 gene mutations in pheochromocytomas and paragangliomas","volume":"304","author":"Yao","year":"2010","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.beem.2020.101416_bib53","doi-asserted-by":"crossref","first-page":"E308","DOI":"10.1210\/jc.2014-2473","article-title":"Penetrance and clinical features of pheochromocytoma in a six-generation family carrying a germline TMEM127 mutation","volume":"100","author":"Toledo","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"9","key":"10.1016\/j.beem.2020.101416_bib54","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/hmg\/ddt638","article-title":"The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function","volume":"23","author":"Qin","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.beem.2020.101416_bib55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Comino-Mendez","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2020.101416_bib56","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1146\/annurev.cellbio.16.1.653","article-title":"The Myc\/Max\/Mad network and the transcriptional control of cell behavior","volume":"16","author":"Grandori","year":"2000","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"10","key":"10.1016\/j.beem.2020.101416_bib57","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin Canc Res : an official journal of the American Association for Cancer Research"},{"issue":"4","key":"10.1016\/j.beem.2020.101416_bib58","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2020.101416_bib59","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cge.13014","article-title":"Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers","author":"Muller","year":"2017","journal-title":"Clin Genet"},{"issue":"9","key":"10.1016\/j.beem.2020.101416_bib60","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.beem.2020.101416_bib61","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMoa073123","article-title":"A\u00a0gain-of-function mutation in the HIF2A gene in familial erythrocytosis","volume":"358","author":"Percy","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.beem.2020.101416_bib62","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1073\/pnas.0508423103","article-title":"A\u00a0family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis","volume":"103","author":"Percy","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"25","key":"10.1016\/j.beem.2020.101416_bib63","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1056\/NEJMoa0806277","article-title":"PHD2 mutation and congenital erythrocytosis with paraganglioma","volume":"359","author":"Ladroue","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2020.101416_bib64","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00109-014-1205-7","article-title":"Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma\/paraganglioma-polycythemia","volume":"93","author":"Yang","year":"2015","journal-title":"J\u00a0Mol Med"},{"issue":"10","key":"10.1016\/j.beem.2020.101416_bib65","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.beem.2020.101416_bib66","doi-asserted-by":"crossref","first-page":"E369","DOI":"10.1210\/jc.2013-2600","article-title":"Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome","volume":"99","author":"Buffet","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"11","key":"10.1016\/j.beem.2020.101416_bib67","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/hmg\/ddt069","article-title":"Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis","volume":"22","author":"Comino-Mendez","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"13","key":"10.1016\/j.beem.2020.101416_bib68","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJMc1716652","article-title":"EPAS1 mutations and paragangliomas in cyanotic congenital heart disease","volume":"378","author":"Vaidya","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2020.101416_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s41436-018-0068-7","article-title":"Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients","author":"Calsina","year":"2018","journal-title":"Genet Med : Official Journal of the American College of Medical Genetics"},{"key":"10.1016\/j.beem.2020.101416_bib70","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1038\/ncomms7044","article-title":"Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas","volume":"6","author":"Castro-Vega","year":"2015","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.beem.2020.101416_bib71","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1101\/gad.1648608","article-title":"The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor","volume":"22","author":"Schlisio","year":"2008","journal-title":"Genes Dev"},{"issue":"7","key":"10.1016\/j.beem.2020.101416_bib72","doi-asserted-by":"crossref","first-page":"E1352","DOI":"10.1210\/jc.2013-4375","article-title":"Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma","volume":"99","author":"Welander","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.beem.2020.101416_bib73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Canc Cell"},{"issue":"1","key":"10.1016\/j.beem.2020.101416_bib74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","article-title":"Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase","volume":"7","author":"Selak","year":"2005","journal-title":"Canc Cell"},{"issue":"6","key":"10.1016\/j.beem.2020.101416_bib75","doi-asserted-by":"crossref","first-page":"E954","DOI":"10.1210\/jc.2011-3437","article-title":"Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations","volume":"97","author":"Loriot","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.beem.2020.101416_bib76","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41379-019-0343-4","article-title":"Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study","volume":"33","author":"Favier","year":"2020","journal-title":"Mod Pathol : an official journal of the United States and Canadian Academy of Pathology, Inc."},{"issue":"8","key":"10.1016\/j.beem.2020.101416_bib77","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S1470-2045(09)70164-0","article-title":"An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis","volume":"10","author":"van Nederveen","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.beem.2020.101416_bib78","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.185","article-title":"Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas","volume":"13","author":"Group NGSiPS","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2020.101416_bib79","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/cen.13246","article-title":"Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers","volume":"86","author":"Tufton","year":"2017","journal-title":"Clin Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2020.101416_bib80","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European association of nuclear medicine practice guideline\/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Taieb","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X20300439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X20300439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:56:56Z","timestamp":1761497816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X20300439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1521690X20300439"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2020.101416","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of 20\u00a0years of genetic studies in pheochromocytoma and paraganglioma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2020.101416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101416"}}